Immutep has reported mature overall survival data from the investigator‑initiated INSIGHT‑003 trial that it says offer a hopeful signal for eftilagimod alfa, known as efti, in first-line non‑squamous non‑small cell lung cancer (NSCLC). …
Immutep cancer candidate shows strong median survival in lung cancer as company consider conflicting trial results
July 13, 2026 Australian Biotech
Latest Video
New Stories
-
Funding for new chemotherapy-free immunotherapy combination for follicular lymphoma
August 3, 2026 - - Latest News -
The HTA Review and the 'Abilene paradox' - when everyone argues for reforms that nobody wants
August 3, 2026 - - Latest News -
First new brain cancer treatment listed on PBS after more than 20 years
August 3, 2026 - - Latest News -
Listing offers treatment option for Australians with tumour induced osteomalacia
August 3, 2026 - - Latest News -
The 'Dispatched' Week in Review' Podcast - 31 July
July 31, 2026 - - Podcast -
New partnership aims to create national blueprint for earlier Alzheimer’s diagnosis and care
July 31, 2026 - - Latest News -
Industry associations still resisting non-disclosure agreements for negotiation
July 31, 2026 - - Latest News